| Bioactivity | MEDICA16, an ATP-citrate lyase inhibitor, significantly reduces intracellular TG content in gastrocnemius muscle, and this reduction is accompanied by an increase in insulin sensitivity. MEDICA16 is a selective agonist for GPR40 as well as selective partial agonists for GPR120[1][2]. | ||||||||||||
| Name | MEDICA16 | ||||||||||||
| CAS | 87272-20-6 | ||||||||||||
| Formula | C20H38O4 | ||||||||||||
| Molar Mass | 342.51 | ||||||||||||
| Appearance | Oil | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Atkinson LL, et al. MEDICA 16 inhibits hepatic acetyl-CoA carboxylase and reduces plasma triacylglycerol levels in insulin-resistant JCR: LA-cp rats. Diabetes. 2002;51(5):1548-1555. [2]. Hara T, Hirasawa A, Sun Q, et al. Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn Schmiedebergs Arch Pharmacol. 2009;380(3):247-255. |